SITE002-0235

SITE002 (USA) › SITE002-0235

SITE002-0235

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2026-06-05

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-08 (study day 83); relationship: NOT RELATED

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-27 (study day 74); relationship: NOT RELATED

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 72); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.